Hers vs MEDVi: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

52 providers verified independently·Independent researchHow we rank →

MEDVi beats Hers overall, scoring 7.7/10 vs 7.3/10. MEDVi is more affordable at $179/mo vs $199/mo. Choose Hers for women who want brand-name wegovy (injection or pill) at $149. Choose MEDVi for users who want a low entry price with oral and injectable co.

A side-by-side look at Hers and MEDVi to help you decide. We compare them on:

  • Starting price per month
  • Our overall score, out of 10
  • Medication type, brand-name or compounded
  • Whether they accept insurance
  • Who each one is best for

Hers

#34 of 52
7.3/10

The women's health arm of Hims & Hers Health (NYSE: HIMS). In 2026 Hers signed a direct Novo Nordisk partnership adding FDA-approved Wegovy (pen and pill) at $149/mo and Zepbound via the Lilly partnership, alongside their existing compounded semaglutide and new compounded tirzepatide programs.

Visit Hers
Higher Rated

MEDVi

#20 of 52
7.7/10

MEDVi is a compounded GLP-1 telehealth platform offering both oral tablets and injectable semaglutide and tirzepatide, with micro-dosing options for side-effect-sensitive patients. $179/mo entry pricing, free shipping, and a streamlined intake, one of the broader compounded mixes among independent telehealth providers in 2026.

Visit MEDVi
FeatureHersMEDVi
Our Score7.3/107.7/10
Starting Price$199/mo$179/mo
Medication TypeBothBoth
Insurance AcceptedNoNo
Best ForWomen who want brand-name Wegovy (injection or pill) at $149/mo via the 2026 Novo Nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brandUsers who want a low entry price with oral and injectable compounded options
Ranking#34#20
Get startedVisit HersVisit MEDVi

Pros & Cons Compared

Hers

Pros

  • +2026 Novo Nordisk partnership, FDA-approved Wegovy pen and Wegovy oral pill from $149/mo, one of the lowest brand-name GLP-1 prices on the market
  • +Zepbound access via the Lilly/Hims-Hers partnership announced 2026
  • +Publicly traded company (NYSE: HIMS) with strong financial backing and regulatory compliance
  • +Broader women's health platform, integrates weight loss with hormonal, skin, and wellness services

Cons

  • Membership + medication are billed separately ($39 first month / $149 ongoing membership), so total both line items before comparing prices
  • Support runs at big-platform scale, fine for routine refills, less personal if you want high-touch care
  • Compounded pricing starts at $199/mo with stepped pricing at higher doses, budget for the dose you'll end up on, not the entry dose
  • Zepbound access priced at ~$1,899/mo (brand cash) via the Lilly partnership, read as access, not value

MEDVi

Pros

  • +One of the few compounded providers offering both oral tablets and injectable semaglutide
  • +Micro-dosing options available, can start at sub-standard doses for patients concerned about side effects
  • +Sleek onboarding experience with clear progress tracking through their patient portal
  • +$179/mo is competitive for a platform with both oral and injectable compounded formulations

Cons

  • No brand-name Wegovy or Zepbound on the platform (the 2026 expansion added branded Ozempic only)
  • No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms; you can switch to injectable anytime at no extra fee if results lag

Our Verdict

MEDVi edges out Hers with a score of 7.7/10 vs 7.3/10. If budget is your priority, MEDVi starts at $179/mo compared to Hers's $199/mo. Choose Hers if you want: women who want brand-name wegovy (injection or pill) at $149/mo via the 2026 novo nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand. Choose MEDVi if you want: users who want a low entry price with oral and injectable compounded options.

Still undecided? Editor's Featured Pick

TrimRx

$149/mo · 7.8/10 · Compounded

If neither Hers nor MEDVi feels like the right fit, our featured pick across all 52 GLP-1 telehealth providers is TrimRx. It is not the highest-scored provider in our full rankings. We feature it for its low-friction value: a flat $149/mo that stays the same at every dose.

Try Hers

Starting at $199/mo

Visit Hers

Try MEDVi

Starting at $179/mo

Visit MEDVi

Related comparisons

Other matchups readers comparing Hers or MEDVi tend to look at next.

Not sure which one is right for you?

Answer a few quick questions and we'll match you to the best GLP-1 provider for your needs. Or keep exploring below.

Featured Partners

Four affiliate partners we feature, we may earn a commission.

TrimRx

7.8/10
$149/mo·Compounded

Gala

7.2/10
$149/mo·Brand & Compounded

SkinnyRx

7.3/10
$199/mo·Compounded

Embody

7.3/10
$149/mo·Compounded

Affiliate links, we earn a commission at no extra cost to you. These are featured partners, prioritized by our affiliate economics, not an editorial "best" ranking. The objective ranking (by methodology score) and full methodology are at glp1picks.com/best.